von Eyss Research Group

Selected Publications

  • TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells.
    Elster* D, Tollot* M, Schlegelmilch K, Ori A, Rosenwald A, Sahai E, von Eyss B
    Nat Commun 2018, 9(1), 3115 * equal contribution
  • Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation.
    Jaenicke* LA, von Eyss* B, Carstensen A, Wolf E, Xu W, Greifenberg AK, Geyer M, Eilers M, Popov N
    Mol Cell 2016, 61(1), 54-67 * equal contribution
  • Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells.
    Wiese* KE, Haikala* HM, von Eyss* B, Wolf E, Esnault C, Rosenwald A, Treisman R, Klefström J, Eilers M
    EMBO J 2015, 34(11), 1554-71 * equal contribution
  • A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer.
    von Eyss B, Jaenicke LA, Kortlever RM, Royla N, Wiese KE, Letschert S, McDuffus LA, Sauer M, Rosenwald A, Evan GI, Kempa S, Eilers M
    Cancer Cell 2015, 28(6), 743-57
  • The SNF2-like helicase HELLS mediates E2F3-dependent transcription and cellular transformation.
    von Eyss B, Maaskola J, Memczak S, Möllmann K, Schuetz A, Loddenkemper C, Tanh MD, Otto A, Muegge K, Heinemann U, Rajewsky N, Ziebold U
    EMBO J 2012, 31(4), 972-85
  • The human synMuv-like protein LIN-9 is required for transcription of G2/M genes and for entry into mitosis.
    Osterloh* L, von Eyss* B, Schmit F, Rein L, Hübner D, Samans B, Hauser S, Gaubatz S
    EMBO J 2007, 26(1), 144-57 * equal contribution

Publications at FLI

2024

  • Denervation alters the secretome of myofibers and thereby affects muscle stem cell lineage progression and functionality.
    Henze H, Hüttner SS, Koch P, Schüler SC, Groth M, von Eyss B, von Maltzahn J
    NPJ Regen Med 2024, 9(1), 10
  • Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers.
    Jessen* M, Gertzmann* D, Liss* F, Zenk F, Bähner L, Schöffler V, Schulte C, Maric HM, Ade CP, von Eyss** B, Gaubatz** S
    Oncogene 2024 (epub ahead of print) * equal contribution, ** co-corresponding authors

2023

  • A YIPF5-GOT1A/B complex directs a transcription-independent function of ATF6 in ER export
    Cramer P, Yonemura Y, Behrendt L, Marszalek A, Sannai M, Durso W, Günes C, Szafranski K, Nakamura N, Nasrashvili T, Mayer J, von Eyss** B, Kaether** C
    bioRxiv 2023, 10.1101/2023.12.12.569033 ** co-corresponding authors
  • A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
    Hüttner SS, Henze H, Elster D, Koch P, Anderer U, von Eyss B, von Maltzahn J
    Mol Ther 2023, 31(9), 2612-32
  • Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
    Jessen M, Gertzmann D, Liss F, Zenk F, Bähner L, Schöffler V, Ade CP, von Eyss B, Gaubatz S
    bioRxiv 2023, 10.1101/2023.07.27.550917
  • Taz protects hematopoietic stem cells from an aging-dependent decrease in PU.1 activity
    Kim KM
    Dissertation 2023, Jena, Germany
  • A noncanonical repressor function of JUN restrains YAP activity and suppresses YAP-dependent liver cancer growth
    Kurlishchuk* Y, Cindric Vranesic* A, Jessen* M, Kipping A, Kim K, Cramer P, von Eyss B
    bioRxiv 2023, 10.1101/2023.08.20.554005 * equal contribution
  • Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.
    Straube* J, Eifert* T, Vu T, Janardhanan Y, Haldar R, von Eyss B, Cooper L, Bruedigam C, Ling VY, Cooper E, Patch AM, Bullinger L, Schnoeder TM, Bywater M, Heidel* FH, Lane* SW
    Leukemia 2023, 37(4), 741 * equal contribution
  • TRPS1 maintains luminal progenitors in the mammary gland by repressing SRF/MRTF activity
    Tollot-Wegner M, Jessen M, Kim K, Sanz-Moreno A, Spielmann N, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, von Eyss B
    bioRxiv 2023, 10.1101/2023.11.24.568520
  • Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.
    Tubío-Santamaría N, Jayavelu AK, Schnoeder TM, Eifert T, Hsu CJ, Perner F, Zhang Q, Wenge DV, Hansen FM, Kirkpatrick JM, Jyotsana N, Lane SW, von Eyss B, Deshpande AJ, Kühn MWM, Schwaller J, Cammann C, Seifert U, Ebstein F, Krüger E, Hochhaus A, Heuser M, Ori A, Mann M, Armstrong SA, Heidel FH
    Mol Cancer 2023, 22(1), 196